A Mendelian randomisation study of the effect of body mass index on 52 causes of death among 125 000 Mexican adults with admixed ancestry
Gnatiuc Friedrichs L. et al, (2025), International Journal of Epidemiology
An application of the MR-Horse method to reduce selection bias in genome-wide association studies of disease progression.
Donovan K. et al, (2025), Eur J Hum Genet
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
HORBY PW. et al, (2025), The Lancet Infectious Diseases
MORTALITY RISKS IN SUBTYPES OF WHITE-COAT HYPERTENSION: IMPLICATIONS FOR THE DIAGNOSIS OF WHITE-COAT HYPERTENSION
De la Sierra A. et al, (2025), Journal of Hypertension, 43, e11 - e12
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.
Zhu D. et al, (2025), Nephrol Dial Transplant, 40, i70 - i79
Mortality risks in different subtypes of masked hypertension in the Spanish ambulatory blood pressure monitoring registry.
de la Sierra A. et al, (2024), J Hypertens
Resistant Hypertension and Mortality: An Observational Cohort Study.
de la Sierra A. et al, (2024), Hypertension, 81, 2350 - 2356
Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial.
O'Hara DV. et al, (2024), BMJ Open, 14
ALDOSTERONE SYNTHASE INHIBITION WITH VICADROSTAT (BI 690517) TO REDUCE RISKS OF KIDNEY AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE: A RATIONALE FOR THE EASi-KIDNEY TRIAL
Judge P. et al, (2024), Nephrology Dialysis Transplantation
A global view on kidney care.
Staplin N., (2024), Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 39, ii1 - ii2
Design, recruitment and baseline characteristics of the LENS trial.
LENS Collaborative Group None., (2024), Diabet Med, 41
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.
Fletcher RA. et al, (2024), Clin J Am Soc Nephrol, 19, 1180 - 1182
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
Apperloo EM. et al, (2024), Lancet Diabetes Endocrinol, 12, 545 - 557
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials
LANDRAY M. et al, (2024), The Lancet Diabetes and Endocrinology